StockNews.AI
VRNA
StockNews.AI
4 hrs

Verona Pharma to Present Additional Analyses of the Phase 3 ENHANCE Studies in COPD at ERS International Congress 2025

1. Verona Pharma presents Phase 3 study analyses for Ohtuvayre at ERS Congress. 2. Ohtuvayre is a first-in-class dual inhibitor for COPD treatment. 3. Data highlights significant benefits for lung function and COPD symptoms. 4. Ensifentrine shows promise for enhancing quality of life in COPD patients. 5. Current developments include a fixed-dose combination therapy for further efficacy.

7m saved
Insight
Article

FAQ

Why Bullish?

The presentation of positive data about Ohtuvayre supports VRNA's market potential. Previous similar announcements have led to stock gains.

How important is it?

The article discusses new clinical data and its implications, crucial for investor sentiment. Positive trial outcomes often lead to heightened investor activity.

Why Short Term?

Immediate investor interest will likely arise from recent conference presentations. Historical patterns show stock reactions align with presentation schedules.

Related Companies

VRTXGILDABBV
September 16, 2025 06:00 ET  | Source: Verona Pharma plc Posters support Ohtuvayre® (ensifentrine) as a first-in-class selective dual inhibitor of PDE3 and PDE4 for a broad COPD population LONDON and RALEIGH, N.C., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona” or the “Company”), a biopharmaceutical company focused on respiratory diseases, announces two posters on additional analyses from its Phase 3 ENHANCE studies with Ohtuvayre (ensifentrine) for the treatment of chronic obstructive pulmonary disease (“COPD”), will be presented at the European Respiratory Society (“ERS”) International Congress 2025. The abstracts are available to conference participants on the ERS website and will be published in an upcoming issue of the peer reviewed publication, European Respiratory Journal. Ohtuvayre (ensifentrine) is a first-in-class selective dual inhibitor of the enzymes phosphodiesterase 3 and 4 (“PDE3 and PDE4”) that combines bronchodilator and non-steroidal anti-inflammatory effects in one molecule. Ohtuvayre is the first novel inhaled mechanism for the maintenance treatment of COPD in more than 20 years. The posters highlight subgroup analyses of the benefits of ensifentrine on lung function, rate and risk of exacerbations, and COPD symptoms, including dyspnea, and quality of life according to baseline dyspnea level. Details of Verona’s posters are listed below and linked to the ERS website: Poster 3613: The effect of ensifentrine on COPD symptoms and quality of life according to baseline dyspnea levelPresenter: Jadwiga A. Wedzicha, MD, Professor of Respiratory Medicine at the National Heart and Lung Institute, Imperial College London, UKSession 306: Unblocking the airways: innovations in mucus-targeted therapy and novel data on phosphodiesterase inhibitorsPoster 3614: The effect of ensifentrine on lung function and exacerbations in patients with COPD according to baseline dyspneaPresenter: Frits M.E. Franssen, MD, Head of the Department of Respiratory Medicine, Maastricht University Medical Center, The NetherlandsSession 306: Unblocking the airways: innovations in mucus-targeted therapy and novel data on phosphodiesterase inhibitors For further information please contact: Verona Pharma plcTel: +1-844-341-9901Victoria Stewart, Senior Director of Investor Relations and CommunicationsIR@veronapharma.comArgot PartnersUS Investor EnquiriesTel: +1-212-600-1902verona@argotpartners.comTen Bridge CommunicationsInternational / US Media EnquiriesTel: +1-781-316-4424tbcverona@tenbridgecommunications.comWendy Ryan    About Ohtuvayre (ensifentrine) Ohtuvayre is the first inhaled therapy for the maintenance treatment of COPD that combines bronchodilator and non-steroidal anti-inflammatory activities in one molecule. Verona has evaluated nebulized Ohtuvayre in its Phase 3 clinical program ENHANCE (“Ensifentrine as a Novel inHAled Nebulized COPD thErapy”) for COPD maintenance treatment. Ohtuvayre met the primary endpoint in both ENHANCE-1 and ENHANCE-2, demonstrating statistically significant and clinically meaningful improvements in lung function. A fixed-dose combination of ensifentrine and glycopyrrolate, a LAMA, is currently under development for the maintenance treatment of COPD. About Verona Pharma Verona Pharma is a biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of chronic respiratory diseases with significant unmet medical needs. Ohtuvayre™ (ensifentrine) is the Company’s first commercial product and the first inhaled therapy for the maintenance treatment of COPD that combines bronchodilator and non-steroidal anti-inflammatory activities in one molecule. Ensifentrine has potential applications in other respiratory diseases such as non-cystic fibrosis bronchiectasis. For more information, please visit www.veronapharma.com. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. All statements contained in this press release other than statements of historical fact should be considered forward-looking statements. Words such as “anticipate,” “believe,” “plan,” “expect,” “intend,” “may,” “potential,” “prepare,” “possible” and similar words and expressions are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the potential benefits and efficacy of our drug Ohtuvayre and future poster presentations and academic publications pertaining to Ohtuvayre. These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from our expectations expressed or implied by the forward-looking statements, including, but not limited to the efficacy of Ohtuvayre compared to competing drugs; and the other important factors discussed under the caption “Risk Factors” in our Quarterly Report on Form 10-Q for the period ended June 30, 2025 filed with the Securities and Exchange Commission (“SEC”) on August 6, 2025, as such factors may be updated from time to time in our other filings with the SEC. We disclaim any obligation to update or revise any forward-looking statement contained in this press release, even if subsequent events cause our views to change, except as required under applicable law.

Related News